SNY and REGN Related Headlines
Go Back- BTIG on Apogee (APGE): 'DUPLEX-AD's Failure is Likely a Clearing Event for APG279 and APG777 in Atopic Dermatitis'
- Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
- William Blair on Sanofi (SNY): 'We believe it will be important to see the efficacy broken out by prior advanced therapy'
- Regeneron (REGN) Shares Decline on the Open
- Lawmakers push to ban direct-to-consumer drug advertising, WSJ reports
